Experimental cancer pill targets rare mutation, but trial halted early
NCT ID NCT06560645
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 35 times
Summary
This early-stage study tested an experimental oral drug called PRT7732 in 42 people with advanced solid tumors that have a SMARCA4 mutation. The goal was to check safety, find the right dose, and see if it shrinks tumors. However, the trial was terminated, so full results are not available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Border Medical Oncology Research Unit
Albury, New South Wales, 2640, Australia
-
Brigitte Harris Cancer Pavilion
Detroit, Michigan, 48202, United States
-
Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, 135-8550, Japan
-
Hospital Universitario HM Sanchinarro
Madrid, 28050, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Kindai University Hospital
Sayama, Osaka, 589-8511, Japan
-
Linear Clinical Research Ltd
Nedlands, Western Australia, 6009, Australia
-
Memorial Sloan Kettering Cancer Center - Main Campus
New York, New York, 10065, United States
-
Monash Health
Clayton, Victoria, 3168, Australia
-
National Cancer Center
Goyang-si, Gyeonggi-do, 10408, South Korea
-
National Cancer Center Hospital
Chuo Ku, Tokyo, 104-0045, Japan
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Scientia Clinical Research Ltd
Randwick, New South Wales, 2031, Australia
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
-
Southern Highlands Cancer Centre
Bowral, New South Wales, 2576, Australia
-
Start Madrid-FJD, Hospital Universitario Fundacion Jimenez Diaz-Servicio de Oncologia
Madrid, 28040, Spain
-
Technische Universitat Dresden, Medizinlsche Fakultat Carl Gustav Carus Nationales Centrum fur Tumorerkrankungen Dresden, Early Clinical Trial Unit (NCT/UCC ECTU)
Dresden, Saxony, 01307, Germany
-
The Univerity of Osaka Hospital
Suita, Osaka, 565-0871, Japan
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158, United States
-
UNC Hospitals, The University of North Carolina Chapel Hill
Chapel Hill, North Carolina, 27514, United States
-
University Clinic Cologne, Clinic for Internal Medicine
Cologne, North Rhine-Westfalia, 50937, Germany
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia, 22903, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PRT7732 (an oral drug that degrades a protein called SMARCA2)
What this could lead to
If it works, this could point toward a new treatment option for people with certain hard-to-treat cancers that have a SMARCA4 mutation.
What could go wrong
This was a very early (Phase 1) study that was terminated, so results are limited. The drug may not be effective or safe in larger groups, and side effects are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.